Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection

The Journal of Immunology : Official Journal of the American Association of Immunologists
Lanying DuBo-Jian Zheng

Abstract

We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-gamma-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and...Continue Reading

References

Dec 22, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·H ChaoC E Walsh
Apr 12, 2003·The New England Journal of Medicine·Thomas G KsiazekUNKNOWN SARS Working Group
Apr 25, 2003·Lancet·J S M PeirisUNKNOWN SARS study group
May 16, 2003·The New England Journal of Medicine·Kathryn V Holmes
Dec 20, 2003·Current Gene Therapy·L TenenbaumP E Monahan
Jan 21, 2004·Acta Biochimica Et Biophysica Sinica·Ping ZhaoZhong-Tian Qi
Feb 14, 2004·Science·Eliot Marshall, Martin Enserink
Apr 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Himani BishtBernard Moss
Jun 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Ursula J BuchholzPeter L Collins
Sep 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael J BlankinshipJeffrey S Chamberlain
Oct 27, 2004·Journal of Alzheimer's Disease : JAD·Hideo HaraTakeshi Tabira
Apr 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yuxian HeShibo Jiang
Jun 25, 2005·Current Gene Therapy·Anne K Zaiss, Daniel A Muruve
Sep 20, 2005·Proceedings of the National Academy of Sciences of the United States of America·Susanna K P LauKwok-Yung Yuen
Oct 1, 2005·Science·Wendong LiLin-Fa Wang
Dec 13, 2005·Cellular Immunology·Maria H NikolovaArmand Bensussan

❮ Previous
Next ❯

Citations

Oct 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fumihiko YasuiMichinori Kohara
Jun 18, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Aaruni KhanolkarJohn T Harty
Apr 16, 2015·Human Vaccines & Immunotherapeutics·Jian TangYusen Zhou
May 10, 2020·Expert Opinion on Biological Therapy·Leticia Moreno-FierrosSergio Rosales-Mendoza
Jun 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Bo-Jian ZhengKwok-Yung Yuen
Feb 10, 2009·Nature Reviews. Microbiology·Lanying DuShibo Jiang
May 16, 2019·Journal of Immunology Research·Ayman MubarakMaged Gomaa Hemida
Aug 8, 2020·AAPS PharmSciTech·Jieliang WangRobert O Williams
Apr 29, 2014·Expert Review of Vaccines·Naru ZhangLanying Du
Sep 29, 2020·Human Antibodies·Sara AssadiaslMohammad Hossein Nicknam
Jun 10, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ashley L St John, Abhay P S Rathore
Aug 4, 2020·Infectious Diseases of Poverty·Hong-Zhi ChenXiang Wu
Jul 3, 2020·Frontiers in Immunology·Luis F García
Aug 1, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Daniel P Otto, Melgardt M de Villiers
Mar 21, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yuxian HeSara Lustigman
Mar 29, 2011·Expert Opinion on Drug Delivery·Fabian BlankChristophe von Garnier
May 12, 2020·Frontiers in Microbiology·Longping V TseRalph S Baric
Sep 16, 2020·Human Vaccines & Immunotherapeutics·Rajat MudgalShailly Tomar
Jun 23, 2009·Expert Review of Vaccines·Rachel L Roper, Kristina E Rehm
Oct 18, 2020·Nature Reviews. Microbiology·Shan SuShibo Jiang
Oct 21, 2020·Alcohol·Kristina L BaileyTodd A Wyatt
Feb 13, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ramandeep SinghZhou Xing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.